Baseline characteristic | Patients with SRP after 3 years | ||
---|---|---|---|
No (n=63) | Yes (n=33) | Total (n=96) | |
Age, years | 55.4 (12.5) | 51.3 (13.4) | 54.0 (12.9) |
Female, n (%) | 53 (84) | 26 (79) | 79 (82) |
Disease duration, years | 7.3 (5.8) | 5.8 (4.7) | 6.8 (5.5) |
Swollen joints | 21.8 (10.6) | 22.4 (9.7) | 22.0 (10.2) |
Tender joints | 32.4 (13.4) | 33.7 (13.4) | 32.8 (13.3) |
ESR, mm/h | 35.2 (23.8) | 54.3 (28.5) | 41.8 (26.9) |
CRP, mg/L | 18.5 (20.8) | 43.2 (35.5) | 26.9 (29.0) |
RF positive, n (%) | 34 (54) | 28 (85) | 62 (65) |
HAQ | 1.7 (0.6) | 1.8 (0.6) | 1.7 (0.6) |
mTSS | 31.1 (53.6) | 40.7 (47.8) | 34.4 (51.7) |
Erosion score | 13.6 (29.6) | 18.2 (25.4) | 15.2 (28.2) |
MTX dose, mg/week | – | – | 7.40 (0.62) |
Data presented as mean (SD) unless otherwise stated.
CRP, C reactive protein; ESR, erythrocyte sedimentation rate; HAQ, health assessment questionnaire; mTSS, modified Sharp/van der Heijde; MTX, methotrexate; RF, rheumatoid factor; SRP, significant radiographic progression.